Aggregated price index with volume information
Summary:
- Alzheimer Treatment stocks up 3.0% on average while median return up 0.9% in a day
- Alzheimer Treatment stocks up 5.2% on average while median return up 0.0% in a week
- Alzheimer Treatment stocks down 7.2% on average while median return down 10.5% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $ANVS 49.7%, $SAVA 9.4%
- 1M losers are : Losers for past month are $ACIU -22.4%, $WVE -22.8%, $ATHA -25.0%, $DNLI -25.7%, $AVXL -32.0%
- 1W winners are : Winners for past week are $ANVS 79.0%, $SAVA 13.7%, $AXSM 5.6%, $MRK 4.3%, $IONS 2.2%
- 1W losers are : Losers for past week are $DNLI -3.6%, $ABBV -4.1%, $WVE -4.3%, $AVXL -9.0%, $ATHA -9.9%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 24.2%, for the past 3 months is 15.2%
In the past month for a 5 days rolling window, the highest corrrelation is 44.0%, the lowest correlation is 7.2%, the latest correlation is 14.3%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 69.6% between AVXL and DNLI
The lowest correlation is -41.4% between ACIU and VYGR
AbbVie is "firing on all cylinders," an analyst said Friday after the firm beat first-quarter estimates. But AbbVie stock fell.
Investors are struggling to see past the end of Humira's dominance.
ABBV earnings call for the period ending March 31, 2024.
All three of the major indexes (^DJI,^GSPC, ^IXIC) are jumping on better-than-expected quarterly results from Alphabet (GOOG, GOOGL) and Microsoft (MSFT). The earnings are providing evidence to investors that artificial intelligence is more than hype; there is a lot of cash being spent on the tech. Wall Street is also digesting another inflation report. The core March Personal Consumption Expenditures reading was slightly hotter than expected, but not enough to deter expectations that the Federa...
AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.
Some companies, however, reported a market capitalisation decline, including Gilead Sciences and Roche.
PCE/Core PCE Numbers Came In Line With Expectations
Pre-market futures are up across the board: +106 points on the Dow, +45 points on the S&P 500 and +195 on the Nasdaq immediately following this important data's release.
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AbbVie raised its full-year earnings outlook despite continuing sales declines for autoimmune drug Humira. AbbVie said it expects adjusted earnings in 2024 of between $11.13 and $11.33 a share, up from previous guidance of $10.97 to $11.17 a share. Analysts surveyed by FactSet were expecting the biopharmaceutical company to post full-year earnings of $11.12 a share.